Evidence of quality of life for hospitalised patients with COVID-19: a scoping review.
COVID-19
HOSPITALISATION
QUALITY OF LIFE
SCOPING REVIEW
Journal
Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
medline:
27
5
2024
pubmed:
27
5
2024
entrez:
27
5
2024
Statut:
aheadofprint
Résumé
Information on the quality of life of people hospitalised with COVID-19 is important, both in assessing the burden of disease and the cost-effectiveness of treatments. However, there were potential barriers to collecting such evidence. To review the existing evidence on quality of life for people hospitalised with COVID-19, with a focus on the amount of evidence available and methods used. A scoping review with systematic searches. A total of 35 papers were selected for data extraction. The most common study type was economic evaluation ( Although it used systematic searches, this was not a full systematic review. Quality-of-life data were collected from people hospitalised with COVID-19 from relatively early in the pandemic. However, there was a lack of consensus as to what survey measures to use, and few studies used generic health measures. Economic evaluations for COVID-19 treatments did not use utilities collected from people with COVID-19. In future health crises, researchers should be vigilant for opportunities to collect quality-of-life data from hospitalised patients but should try to co-ordinate as well as ensuring generic health measures are used more. This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Quality of life can be measured using short, simple surveys. It is important to assess quality of life in this way, as it can show how health conditions affect people. Quality-of-life surveys can also be used to measure how treatments benefit people and to judge whether it is cost-effective to fund them. COVID-19 is a new disease, with new treatments developed to treat it. COVID-19 also created possible barriers to collecting quality-of-life survey data, especially from people in hospital at the start of the pandemic. This paper reviews studies which report data on quality of life for people hospitalised with COVID-19, especially how much evidence is available and how the studies were carried out. There were 35 studies included in the review. Of these, 13 assessed how cost-effective treatments for COVID-19 were. None of them collected survey responses directly from patients. Instead, they used data previously collected from people with other conditions such as influenza to represent people with COVID-19’s quality of life. The studies which did collect data from patients used a wide variety of different surveys, which made comparing their results difficult. Mental health-related surveys were used by 12 studies, and a further 12 used sleep-related surveys. Relatively few studies used general surveys which could assess the overall effect of COVID-19 on people’s quality of life. In future health crises, we recommend using more general quality-of-life measures. We also recommend that researchers co-ordinate to reduce the number of different surveys they use, as this will make comparing results easier.
Sections du résumé
Background
UNASSIGNED
Information on the quality of life of people hospitalised with COVID-19 is important, both in assessing the burden of disease and the cost-effectiveness of treatments. However, there were potential barriers to collecting such evidence.
Objective
UNASSIGNED
To review the existing evidence on quality of life for people hospitalised with COVID-19, with a focus on the amount of evidence available and methods used.
Design
UNASSIGNED
A scoping review with systematic searches.
Results
UNASSIGNED
A total of 35 papers were selected for data extraction. The most common study type was economic evaluation (
Limitations
UNASSIGNED
Although it used systematic searches, this was not a full systematic review.
Conclusion
UNASSIGNED
Quality-of-life data were collected from people hospitalised with COVID-19 from relatively early in the pandemic. However, there was a lack of consensus as to what survey measures to use, and few studies used generic health measures. Economic evaluations for COVID-19 treatments did not use utilities collected from people with COVID-19. In future health crises, researchers should be vigilant for opportunities to collect quality-of-life data from hospitalised patients but should try to co-ordinate as well as ensuring generic health measures are used more.
Funding
UNASSIGNED
This article presents independent research funded by the National Institute for Health and Care Research (NIHR)
Quality of life can be measured using short, simple surveys. It is important to assess quality of life in this way, as it can show how health conditions affect people. Quality-of-life surveys can also be used to measure how treatments benefit people and to judge whether it is cost-effective to fund them. COVID-19 is a new disease, with new treatments developed to treat it. COVID-19 also created possible barriers to collecting quality-of-life survey data, especially from people in hospital at the start of the pandemic. This paper reviews studies which report data on quality of life for people hospitalised with COVID-19, especially how much evidence is available and how the studies were carried out. There were 35 studies included in the review. Of these, 13 assessed how cost-effective treatments for COVID-19 were. None of them collected survey responses directly from patients. Instead, they used data previously collected from people with other conditions such as influenza to represent people with COVID-19’s quality of life. The studies which did collect data from patients used a wide variety of different surveys, which made comparing their results difficult. Mental health-related surveys were used by 12 studies, and a further 12 used sleep-related surveys. Relatively few studies used general surveys which could assess the overall effect of COVID-19 on people’s quality of life. In future health crises, we recommend using more general quality-of-life measures. We also recommend that researchers co-ordinate to reduce the number of different surveys they use, as this will make comparing results easier.
Autres résumés
Type: plain-language-summary
(eng)
Quality of life can be measured using short, simple surveys. It is important to assess quality of life in this way, as it can show how health conditions affect people. Quality-of-life surveys can also be used to measure how treatments benefit people and to judge whether it is cost-effective to fund them. COVID-19 is a new disease, with new treatments developed to treat it. COVID-19 also created possible barriers to collecting quality-of-life survey data, especially from people in hospital at the start of the pandemic. This paper reviews studies which report data on quality of life for people hospitalised with COVID-19, especially how much evidence is available and how the studies were carried out. There were 35 studies included in the review. Of these, 13 assessed how cost-effective treatments for COVID-19 were. None of them collected survey responses directly from patients. Instead, they used data previously collected from people with other conditions such as influenza to represent people with COVID-19’s quality of life. The studies which did collect data from patients used a wide variety of different surveys, which made comparing their results difficult. Mental health-related surveys were used by 12 studies, and a further 12 used sleep-related surveys. Relatively few studies used general surveys which could assess the overall effect of COVID-19 on people’s quality of life. In future health crises, we recommend using more general quality-of-life measures. We also recommend that researchers co-ordinate to reduce the number of different surveys they use, as this will make comparing results easier.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-23Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
World Health Organization. COVID-19: Vulnerable and High Risk Groups. 2023. URL: www.who.int/westernpacific/emergencies/covid-19/information/high-risk-groups (accessed 3 August 2023).
Organisation for Economic Co-operation and Development. OECD Science, Technology and Innovation Outlook 2021. 2021.
Nandasena H, Pathirathna M, Atapattu A, Prasanga P. Quality of life of COVID 19 patients after discharge: systematic review. PLOS ONE 2022;17:e0263941.
Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, Patel U. Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL): a systematic review and meta‐analysis. J Med Virol 2022;94:253–62.
Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health 2021;6:e005427.
Horby P, Landray M, Haynes R, Juszczak E, Baillie K, Jaki T. Randomised Evaluation of COVID-19 Therapy (RECOVERY): Study Protocol. Oxford: University of Oxford; 2020.
Butler CC, Hobbs FR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2022;401(10373):281–93.
Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22:1293–302.
World Health Organization. Global COVID-19 Vaccination Strategy in a Changing World, July 2022 Update. Geneva: World Health Organization; 2022.
Arber M, Garcia S, Veale T, Edwards M, Shaw A, Glanville JM. Performance of Ovid MEDLINE search filters to identify health state utility studies. Int J Technol Assess Health Care 2017;33:472–80.
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016;75:40–6.
Akinci T, Melek Basar H. Relationship between sleep quality and the psychological status of patients hospitalised with COVID-19. Sleep Med 2021;80:167–70. https://doi.org/10.1016/j.sleep.2021.01.034
Bayrak M, Cadirci K. The associations of life quality, depression, and cognitive impairment with mortality in older adults with COVID-19: a prospective, observational study. Acta Clin Belg 2022;77(3):588–95. https://doi.org/10.1080/17843286.2021.1916687
Bounoua F, Khannous A, Moubachir H, Serhane H. Evaluation of the quality of life in patients treated for COVID-19 at the Hassan II hospital in Agadir using the MOS SF-36 questionnaire. Eur Respir J 2021;58:PA299. https://doi.org/10.1183/13993003.congress-2021.PA299
Carta A, Conversano C. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients: a hypothetical study. BMC Health Serv Res 2021;21:986. https://doi.org/10.1186/s12913-021-06998-w
Chakrabarti S. Mental health in hospitalised COVID 19 patients in quarantine during second wave in a south Indian private teaching hospital. J Multidiscip Healthc 2021;14:2777–89. https://doi.org/10.2147/JMDH.S330812
Cleary SM, Wilkinson T, Tamandjou Tchuem CR, Docrat S, Solanki GC. Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. BMC Health Serv Res 2021;21:82. https://doi.org/10.1186/s12913-021-06081-4
Congly SE, Varughese RA, Brown CE, Clement FM, Saxinger L. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep 2021;11:17787. https://doi.org/10.1038/s41598-021-97259-7
Covino M, Russo A, Salini S, De Matteis G, Simeoni B, Pirone F, et al. Long-term effects of hospitalization for COVID-19 on frailty and quality of life in older adults >=80 years. J. Clin. Med. 2022;11(19):5787. https://doi.org/10.3390/jcm11195787
Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging therapies for COVID-19: the value of information from more clinical trials. Value Health 2022;27:27. https://doi.org/10.1016/j.jval.2022.03.016
Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res 2021;7:00108. https://doi.org/10.1183/23120541.00108-2021
Gunes A, Sensoy B. Sleepiness, insomnia, and sleep quality of hospitalized patients with coronavirus disease-2019: sleep scale evaluation. J Turk Sleep Med 2022;9(1):11–5. https://doi.org/10.4274/jtsm.galenos.2021.39974
Hayden MC, Limbach M, Schuler M, Merkl S, Schwarzl G, Jakab K, et al. Effectiveness of a three-week inpatient pulmonary rehabilitation program for patients after COVID-19: a prospective observational study. Int J Environ Res Public Health 2021;18(17). https://doi.org/10.3390/ijerph18179001
He M, Li X, Tan Q, Chen Y, Kong Y, You J, et al. Disease burden from COVID-19 symptoms among inpatients at the temporary military hospitals in Wuhan: a retrospective multicentre cross-sectional study. BMJ Open 2021;11:e048822. https://doi.org/10.1136/bmjopen-2021-048822
Huang S, Zhuang W, Wang D, Zha L, Xu X, Li X, et al. Persistent somatic symptom burden and sleep disturbance in patients with COVID-19 during hospitalization and after discharge: a prospective cohort study. Med Sci Monit 2021;27: e930447. https://doi.org/10.12659/MSM.930447
Jovanoski N, Kuznik A, Becker U, Hussein M, Briggs A. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. J Manag Care Spec Pharm 2022;28:555–65. https://doi.org/10.18553/jmcp.2022.21469
Kairu A, Were V, Isaaka L, Agweyu A, Aketch S, Barasa E. Modelling the cost-effectiveness of essential and advanced critical care for COVID-19 patients in Kenya. BMJ Glob 2021;6:e007168. https://doi.org/10.1136/bmjgh-2021-007168
Karaogullarindan A, Erkan SO, Tuhanioglu B, Kuran G, Gorgulu O. Sleep quality in patients over 65 years of age in the Covid-19 pandemic. Turk Geriatri Dergisi 2021;24(3):381–90. https://doi.org/10.31086/tjgeri.2021.235
Kelton K, Klein T, Murphy D, Belger M, Hille E, McCollam PL, et al. Cost-effectiveness of combination of Baricitinib and Remdesivir in hospitalized patients with COVID-19 in the United States: a modelling study. Adv Ther 2022;39:562–82. https://doi.org/10.1007/s12325-021-01982-6
Kokhan S, Kolokoltsev M, Vorozheikin A, Gryaznykh А, Romanova E, Guryanov M, et al. Physical rehabilitation of patients with post-COVID syndrome. J Phys Educ Sport 2022;22:2005–11. https://doi.org/10.7752/jpes.2022.09255
Kowal S, Ng CD, Schuldt R, Sheinson D, Cookson R. The impact of funding inpatient treatments for COVID-19 on health equity in the United States: a distributional cost-effectiveness analysis. Value Health 2022;26:216–25. https://doi.org/10.1016/j.jval.2022.08.010
Li J, Zhang YY, Cong XY, Ren SR, XM T. Wu JF 5-min mindfulness audio induction alleviates psychological distress and sleep disorders in patients with COVID-19. World J Clin Cases 2022;10(2):576–84. https://doi.org/10.12998/wjcc.v10.i2.576
Li X, Cai Q, Jia Z, Liu L, Zhou Y, Zhang B, et al. The correlation between mental health status, sleep quality, and inflammatory markers, virus negative conversion time among patients confirmed with 2019-nCoV during the COVID-19 outbreak in China: an observational study. Medicine 2021;100(27):e26520. https://doi.org/10.1097/MD.0000000000026520
Moretti A, Belfiore A, Bianco M, Liguori S, Paoletta M, Toro G, et al. Functioning issues in inpatients affected by COVID-19-related moderate pulmonary impairment: a real-practice observational study. J Int Med Res 2022;50:211266. https://doi.org/10.1177/03000605221126657
Moseholm E, Midtgaard J, Bollerup S, Apol AD, Olesen OB, Jespersen S, Weis N. Psychological distress among hospitalized COVID-19 patients in Denmark during the first 12 months of the pandemic. Int J Environ Res Public Health 2022;19:10097. https://doi.org/10.3390/ijerph191610097
Ohsfeldt R, Kelton K, Klein T, Belger M, Mc Collam PL, Spiro T, et al. Cost-effectiveness of Baricitinib compared with standard of care: a modeling study in hospitalized patients with COVID-19 in the United States. Clin Ther 2021;43:1877–93.e4. https://doi.org/10.1016/j.clinthera.2021.09.016
Oksuz E, Malhan S, Gonen MS, Kutlubay Z, Keskindemirci Y, Jarrett J, et al. Cost-effectiveness analysis of Remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther 2021;38:4935–48. https://doi.org/10.1007/s12325-021-01874-9
Ouanes S, Al-Amin H, Hussein NB, Khan F, Al Shahrani A, David P, et al. Physical and psychosocial well-being of hospitalized and non-hospitalized patients with COVID-19 compared to the general population in Qatar. Front Psychiat 2021;12:792058. https://doi.org/10.3389/fpsyt.2021.792058
Pass B, Vajna E, Knauf T, Rascher K, Aigner R, Eschbach D, et al.; Registry for Geriatric Trauma (ATR-DGU). COVID-19 and proximal femur fracture in older adults: a lethal combination? An analysis of the Registry for Geriatric Trauma (ATR-DGU). J Am Med Dir Assoc 2022;23:576–80. https://doi.org/10.1016/j.jamda.2021.09.027
Rafia R, Martyn-St James M, Harnan S, Metry A, Hamilton J, Wailoo A. A cost-effectiveness analysis of Remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value Health 2022;25:761–9. https://doi.org/10.1016/j.jval.2021.12.015
Samushiya MA, Kryzhanovsky SM, Ragimova AA, Berishvili TZ, Chorbinskaya SA, Ivannikova EI. Psychoemotional disorders and sleep impairments in patients with COVID-19. Neurosci Behav Physiol 2022;52(2):231–5. https://doi.org/10.1007/s11055-022-01229-z
Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther 2021;38:1811–31. https://doi.org/10.1007/s12325-021-01654-5
Tapan OO, Tapan U, Alasan F, Akgul AF, Genc S. Factors that affect sleep quality in hospitalized patients with COVID-19 pneumonia. J Turk Sleep Med 2022;9(1):51–6. https://doi.org/10.4274/jtsm.galenos.2021.86648
Taskesen B, Kardas O, Yilmaz K. Evaluation of depression, anxiety and posttraumatic stress response levels of children and adolescents treated with COVID-19. Eur J Pediatr 2022;182:567–74. https://doi.org/10.1007/s00431-022-04713-3
Whittington MD, Pearson SD, Rind DM, Campbell JD. The cost-effectiveness of Remdesivir for hospitalized patients with COVID-19. Value Health 2022;25:744–50. https://doi.org/10.1016/j.jval.2021.11.1378
Wimmer C, Egger M, Bergmann J, Huge V, Muller F, Jahn K. Critical COVID-19 disease: clinical course and rehabilitation of neurological deficits. Front Neurol 2022;13:1012685. https://doi.org/10.3389/fneur.2022.1012685
Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEcon 1998;13:397–409.
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204–22.
Beck AT, Epstein N, Brown G, Steer R. Beck Anxiety Inventory. J Consult Clin Psychol 1993;56(6):893–7.
Beck AT, Steer RA, Brown GK. Beck Depression Inventory. New York: Harcourt Brace Jovanovich; 1987.
Kovacs M. Child Depression Inventory. Person Individ Diff 1992. https://doi.org/10.1037/t19482-000
Steinberg AM, Brymer MJ, Decker KB, Pynoos RS. The University of California at Los Angeles Post-Traumatic Stress Disorder Reaction Index. Curr Psychiatry Rep 2004;6:96–100.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–5.
Group TE. EuroQol: a new facility for the measurement of health-related quality of life. Health Pol 1990;16:199–208.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7.
Mollica RF, Caspi-Yavin Y, Bollini P, Truong T, Tor S, Lavelle J. The Harvard Trauma Questionnaire: validating a cross-cultural instrument for measuring torture, trauma, and posttraumatic stress disorder in Indochinese refugees. J Nerv Ment Dis 1992;180:111–6.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.
Morin CM. Insomnia: Psychological Assessment and Management. New York: Guilford Press; 1993.
Muza SR, Silverman MT, Gilmore GC, Hellerstein HK, Kelsen SG. Comparison of scales used to quantitate the sense of effort to breathe in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990;141:909–13.
Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. Significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257–66.
Smets E, Garssen B, Bonke B, De Haes J. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315–25.
Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann 2002. pp. 509–15. https://doi.org/10.3928/0048-5713-20020901-06
Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1994;10:385–96. https://doi.org/10.2307/2136404
Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, Neer SM. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiat 1997;36:545–53.
Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971;12(6):371–9. https://doi.org/10.1016/S0033-3182(71)71479-0
Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.
Hays RD, Sherbourne CD, Mazel RM. The rand 36‐item health survey 10. Health Econ 1993;2:217–27.
Duan W, Li J. Short Inventory of Mindfulness Capability. Front Psychol 2016. https://psycnet.apa.org/doi/10.1037/t58213-000
Gierk B, Kohlmann S, Kroenke K, Spangenberg L, Zenger M, Brähler E, Löwe B. The Somatic Symptom Scale–8 (SSS–8): a brief measure of somatic symptom burden. JAMA Intern Med 2014;174:399–407.
Power M, Quinn K, Schmidt S; WHOQOL-OLD Group. Development of the WHOQOL-old module. Qual Life Res: Int J Qual Life Asp Treat Care Rehabil 2005;14:2197–214.
Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397:72–4.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al.; 2019nCoV-302 Study Group. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021;385:1172–83.
Herrera MS, Elgueta R, Fernández MB, Giacoman C, Leal D, Marshall P, et al. A longitudinal study monitoring the quality of life in a national cohort of older adults in Chile before and during the COVID-19 outbreak. BMC Geriatr 2021;21:1–12.
Ishikawa H, Kato M, Kiuchi T. Declines in health literacy and health-related quality of life during the COVID-19 pandemic: a longitudinal study of the Japanese general population. BMC Publ Health 2021;21:1–9.
Willner P, Rose J, Stenfert Kroese B, Murphy GH, Langdon PE, Clifford C, et al. Effect of the COVID‐19 pandemic on the mental health of carers of people with intellectual disabilities. J Appl Res Intel Disab 2020;33:1523–33.
Mak HW, Bu F, Fancourt D. Mental health and wellbeing amongst people with informal caring responsibilities across different time points during the COVID-19 pandemic: a population-based propensity score matching analysis. Perspectives in Public Health 2023;143(5):275–84. https://doi.org/10.1177/175791392211049
Whitley E, Reeve K, Benzeval M. Tracking the mental health of home-carers during the first COVID-19 national lockdown: evidence from a nationally representative UK survey. Psychol Med 2021;53:1096–105.
AUHE Information Specialists. Checking for Duplicates Guidance. Leeds: University of Leeds; 2016.